Mandate

Vinge has advised Azelio in connection with its rights issue

Vinge has advised Azelio AB (publ) on a fully guaranteed rights issue, which will provide Azelio with issue proceeds amounting to approximately SEK 300 million before deduction of transaction costs.

The new shares and warrants issued by reason of the rights issue are expected to be admitted to trading on Nasdaq First North Growth Market on 31 October 2022.

Azelio is a public Swedish company, specializing in in energy storage with electricity and heat production. Azelio’s system (“TES.POD “) for renewable, Stirling-based electricity production and heat production is based on continuous technological development and refinement. The technology makes the energy dispatchable, enabling renewable energy to be made available around-the-clock.

Azelio’s shares are listed on Nasdaq First North Growth Market.

Vinge’s team consisted primarily of David Andersson, William Kåge, Joel Magnusson, Benjamin Vafaeian and Joacim Malmqvist.

 

Related

Vinge advises Right Side Group, a portfolio company of Alder, in connection with the acquisition of Brandkonsultbyrån i Sverige

Brandkonsultbyrån in Sweden is a technical consultant specialising in structural fire protection, evacuation safety and risk management. The acquisition strengthens the group’s position as a leading player in fire, risk and safety in the Nordic region.
April 17, 2026

Vinge advises Vidia Climate Fund I in connection with the acquisition and acquisition financing of ABEKA El & Kraftanläggningar AB

Vinge has acted as legal adviser to Vidia Climate Fund I in connection with the acquisition and acquisition financing of ABEKA El & Kraftanläggningar AB from Bravida and certain minority shareholders. ABEKA El & Kraftanläggningar AB is a highly specialized electrical grid services and project management provider.
April 17, 2026

Vinge adviser in the sale of SAGA Diagnostics

Vinge acted as legal adviser relating to Swedish law in connection with the sale of SAGA Diagnostics to Roche’s subsidiary Foundation Medicine.
April 16, 2026